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Abstract: Approved in 2006, the Human Papillomavirus (HPV) vaccine provided a medical
breakthrough in combating cancer by inoculating first female and then male adolescents in 2010. In 2016,
a new HPV vaccine was approved for all adolescents. However, it is the most expensive vaccine created
in the United States and its female centered prescription led to debates regarding the vaccine’s necessity
and risks. For the STS portion of this paper, analysis of the language in the vaccine’s prescriptions from
2006, 2010, and 2016 demonstrates two implicit assumptions regarding female health built into the
vaccine’s rollout. Comparison of the two assumptions to the popular media campaigns and parental
responses over time shows that as male vaccination became more common and the list of HPV-related
cancers grew, debates regarding its effect on sexual behaviors were dampened. However, distrust of the
vaccine due to corporate marketing grew. The second part of the study uses the net-present value
calculation to identify whether administering the vaccine is cost-effective by comparing the marginal
benefit of the medical treatment and mortality costs foregone and the marginal cost of the two-dose
vaccination per individual. The calculations demonstrate that vaccination at 2018 rates and full
vaccination are not cost-effective at the current price and dose schedule. Overall, this study finds that
there are still stereotyping effects on adolescent girls from the 2006 prescriptions and that funding for the
vaccine’s development is not cost-effective and could be used in other medical interventions.
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1. INTRODUCTION
The intersection between gender and medicine is a common topic of discussion among
Science, Technology, Society (STS) scholars. The lenses of philosophy, history, and social
science are important components of the STS field that enable scholars to better understand how
gender shapes medical care. A key topic in healthcare economics is interpreting the costeffectiveness of medical technologies, such as vaccinations. Both analyses can be applied to
studying the Human Papillomavirus (HPV) vaccine, first approved in the United States in 2006
for female adolescents and in 2010 for male adolescents.1 The present study indicates a
relationship between the sexualization and feminization of the HPV vaccine and the public
uptake rates, a pattern similar to what occurred when oral contraceptives came to the market,
according to physician Ellen Daley.2
The aim of this paper is twofold: To use scientific documentation and popular media to
better understand why prescriptions around the HPV vaccine administration changed in the U.S.
and how the changes impacted uptake levels and gendered ideals in sexual health. This
investigation argues that the debate surrounded more cultural than medical concerns regarding
the vaccine and that these concerns from parents differ from the assumptions found in the
prescription’s language. An example of a cultural concern was that the vaccine could be
introducing the idea of risky sexual practices at an earlier age versus a medical concern that the
vaccine could reduce progressive cervical cancer cell development in women. The second aim of
this study is to determine whether HPV inoculation is cost-effective as a cervical and
oropharyngeal cancer prevention method at 2018 vaccination levels and 100% vaccination.

“Human Papillomavirus (HPV) Vaccines,” National Cancer Institute, last modified 2021. 1.
Ellen M. Daley et al., “The feminization of HPV: How science, politics, economics, and gender norms shaped U.S.
HPV vaccine implementation,” Papillomavirus Res. 3, (2017): 143.
1
2
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To investigate the first goal, the paper will apply a social studies lens to identify the assumptions
within the vaccine’s prescription recommendations. The second section will analyze the themes
in medical studies and popular media and compare them to the concerns found in parental
communities. Then a cost-effectiveness analysis will be applied using a net-present discounted
value model to identify whether the vaccine is an effective use of government funding
considering its high price tag. The second piece of the study finds that HPV inoculation is not
cost-effective at current rates of oropharyngeal and cervical cancer rates in the United States,
which lends some support to parental concerns surrounding its necessity.
1.1. Vaccine Timeline
As science and cultural ideals around medical care evolved, so did the HPV vaccine’s
administration prescriptions. This section offers history regarding HPV research and defines the
three main turning points, as seen in Figure 1, for the vaccine’s administration and how they
altered the patient pool by changing the sex and age of the patients being given the vaccine.
Figure 1.

Figure 1. The figure shows the three years where the CDC/FDA revised the HPV vaccine prescriptions.
Source: CDC/FDA

In 1979 epidemiologists began observing links between cervical cancer and sexually
transmitted diseases, and in 1984, German researcher Harald zur Hausen isolated HPV 16 and 18
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from squamous cell carcinomas of the cervix.3 In 1990, scientist Joel Palefsky found that 50% of
a sample of gay men with AIDS had HPV, linking the virus to higher incidences of anal cancer.4
After randomized control trials in 2006, the Food and Drug Administration (FDA)
approved the use of the first HPV vaccine for female patients between the ages of 9 and 26 years
old.5 The 2006 HPV vaccine was a quadrivalent version that protected against the four most
prevalent strains of the virus (types 6, 11, 16, 18).6 It was the first vaccine aimed at combating
cancer, particularly cervical cancer in women. Upon the 2006 FDA approval, the vaccine was
only administered to females to offer inoculation against a sexually transmitted disease (STD)
linked to 70% of cervical cancer cases.7
In late 2007, Merck & Co. launched a large, randomized control trial of the HPV vaccine
in 4,000 healthy men aged 16 to 26 to expand its FDA labeling. The results of these trials were
submitted to the FDA for male vaccine approval in December 2008 with the goal of indirectly
increasing female protection from HPV.8 In August 2009, the FDA approved the HPV vaccine
for males between 10 and 25 years old due to anal cancer concerns and the evidence that
vaccinated males could help reduce HPV cases in female partners.9
In 2015, a Gardasil 9-valent (9v) HPV vaccine was developed to protect against five
additional strains linked to cervical and other cancers (types 31, 33, 45, 52, 58). The 9v vaccine
was found to offer protection against nearly 90%, rather than 70%, of cervical cancers, because
Ellen M. Daley et al., “The feminization of HPV: How science, politics, economics, and gender norms shaped U.S.
HPV vaccine implementation,” Papillomavirus Res. 3, (2017): 143.
4
Ibid.
5
Department of Health and Human Services, “June 8, 2006 Approval Letter- Human Papillomavirus Quadrivalent
Vaccine, Recombinant,” Food and Drug Administration, June 8, 2006.
6
David Yang, “Update on the new 9-valent vaccine for human papillomavirus prevention,” Can Fam Physician 62,
no. 5 (2016): 399.
7
Partha Basu et al., “Efficacy and Safety of Human Papillomavirus Vaccine…,” South Asian J Cancer 2, no. 4
(2013): 188.
8
Keith Wailoo, Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions.
Baltimore: Johns Hopkins University Press, 2010. 42.
9
Ibid.
3
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the five additional strains the 9v vaccine protects against account for 17% of cancerous lesions
linked to HPV.10 The vaccine trials demonstrated increased protection from the vaccines for both
male and female adolescents between the ages of 9 and 15 years old, which led the FDA to make
universal recommendations for the 9vHPV vaccine. As of 2016, the recommendations for the
9vHPV vaccine are that it should be given to all individuals between the ages of 9 and 26,
regardless of gender.11 It should be noted, though, that scientists did not find that the addition of
five strains greatly increased protection against HPV related cancers found in anatomically male
bodies.12 In addition, more recent clinical trials have found correlations between HPV incidence
and oropharyngeal cancer rates in the United States, and rates have been steadily increasing over
the past 20 years.13
2. AIM OF THIS PAPER
The background given thus far demonstrates that medical research had established the
relationship between HPV and cancers, especially anal and cervical cancer, but the timeline of
applying these results differed. Throughout history, women’s health has been the target of
controversy, notably when birth control pills gained increased marketing after more adolescent
females became pregnant in the 1950s.14 The HPV vaccine offers another example of medical
testing, and analyzing its history, prescriptions, and marketing offers insight into cultural ideals
over time. By targeting only females at first, the vaccine opened a debate around promiscuity and
sexual transmission risks. Although the vaccine was pushed as a cancer risk reducing

David Yang, “Update on the new 9-valent vaccine for human papillomavirus prevention,” Can Fam Physician 62,
no. 5 (2016): 400.
11
Keith Wailoo, Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions.
Baltimore: Johns Hopkins University Press, 2010. 44.
12
Ibid.
13
“United States Cancer Statistics Data Visualizations: Oral Cavity and Pharynx Cancer in Males.” Centers for
Disease Control and Prevention, last modified 2018.
14
Keith Wailoo, Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions.
Baltimore: Johns Hopkins University Press, 2010. 113.
10
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technology, vaccine uptake has been slow and reached a high in 2018, where only 61% of
females and 56% of males, between the ages of 13 and 17, had been fully vaccinated against
HPV.15 These rates are below the scientists’ predicted rates of at least 70% vaccination by 2018
and the herd immunity goal of 85% vaccination.16 There might be multiple reasons for this trend,
including the individualized nature of the vaccine, the gendered roll out, and the need for
parental consent for an adolescent to receive immunizations.
The vaccine’s recommendations were set by the FDA and the Centers for Disease
Control and Prevention (CDC), which will be referred to as the health agencies in this paper. It is
the agencies’ research and approval processes that make the vaccine part of a technological
system that can be studied from an STS point of view. This paper argues that the initial
regulations and advice for the HPV vaccine embedded gender values and assumptions, creating a
technical code for dispensing the vaccine. The paper will then analyze how the technical code
changed from a female health centered approach to one more focused on universal societal
health. This argument is made by comparing language in the CDC/FDA reports between 2006
and 2016 and interweaving that language with philosopher Andrew Feenberg’s technical code
(defined in section 2.1.1).
This paper’s first assessment of the CDC guidelines shows that the language over time
became more gender inclusive and less sexually focused, but it also fed into two assumptions
surrounding women’s health: That there was a greater concern for women’s health, and that the
burden of sexual health was placed more on women. Given that HPV cells do not differ between
sexual anatomies, the vaccine itself is not built differently to cater to male vs. female anatomies,

NIS-Teen Survey, “TeenVaxView Publications and Resources,” Center for Disease Control and Prevention, last
modified 2021.
16
Keith Wailoo, Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions.
Baltimore: Johns Hopkins University Press, 2010. 46.
15
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meaning that the chemical component of the vaccine is not gendered. The vaccine not being
chemically gendered is useful in knowing how the vaccine’s system was adapted to medical
concerns of the health agencies. Following this, further analysis shows how different the focus of
the media was to the changes in prescription language and how focused it was on countering
points from parental debates. Put together, the analysis will show that the vaccine’s prescription
was rooted in stereotypes regarding women’s health as being more crucial and sexually charged
than men’s health, stereotypes echoed in parental concerns regarding vaccinating their children.
However, even as the prescription language became more gender neutral, parental concerns
remained gendered, which led to a stagnating vaccination uptake rate.
2.1. STS Literature Review
The original 2006 vaccine was tailored towards directly protecting women from cervical
cancer risks, placing women’s health at the forefront of the recommendations. Recommendations
for the vaccine’s CDC/FDA prescriptions may reveal the social priorities of the vaccine.
Philosopher Andrew Feenberg defined and applied the idea of the technical code, wherein
“technology adapts to social change and responds to the set of societal values that inform
mechanical design of technology.”17 The economic and social interests of society and scientists
can constitute assumptions built into the technology.
When looking at important design elements of the vaccine’s prescription, the analysis
will consider the initial demographic recommendations and the reasons the health agencies gave
for the vaccine’s approval. The reasons are crucial parts of the technology as vaccines are social
through the purpose they serve, and purposes are in the mind of the interpreter.18 In this case
study, the technological vaccine’s network guides the allocation of vaccination in society. This

17
18

Feenberg, Andrew. “Democratic Rationalization: Technology, Power, and Democracy.” Inquiry 35 (1992): 705.
Ibid., 708.
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allocation information will be analyzed and broken down for each of the three main points of the
vaccine’s timeframe, and then used in the cultural analysis part of this paper. The scientists make
the final choice among the principles guiding the technologically viable options for vaccination
and then they define the solution that society uses to curb disease rates.19 The HPV vaccine
functions as a technological system, including its prescription and roll-out, so the vaccine’s
system can be analyzed as including the parameters on its administration set by the CDC, not just
the contents of the vaccine. Feenberg’s argument will be used to demonstrate the power
technology has on its public perception.
Another idea of study stemming from Feenberg’s argument is rationalization with appeal
to efficiency. Feenberg argues that “a technological network can function in a way that is
deemed efficient by a network of actors without being the best application of it for society.”20
This argument will be used to show that as the vaccine’s prescription changed, parents’
responses and thought processes changed, although perhaps not in the most efficient way. In this
sense, the assumptions that were formed by society’s debates and responses to the vaccine’s
prescriptions should be noted because they express which information regarding the technology
was perceived by, and notable to the parents.
Feenberg’s technical code theory demonstrates the power that public perception can have
on a technology and helps to identify whether the perception can be impacted by technological
revisions. The argument demonstrates that technology can adapt to social change, but also that
social perceptions of medical technology can change in response to the technology changing.
This argument will allow further exploration on what social factors influenced policy reactions
and whether the reactions were addressed in the succeeding prescriptions. Overall, the technical

19
20

Feenberg, Andrew. “Democratic Rationalization: Technology, Power, and Democracy.” Inquiry 35 (1992): 708.
Ibid., 711.
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code argument outlines how to conduct the CDC/FDA source analysis and how research into the
vaccine’s cultural debates should be focused. The following analysis will extend past Feenberg’s
arguments that focus on artifacts and apply them to the HPV vaccine’s system.
The first part of this paper will also utilize arguments from Three Shots at Prevention,
edited by Keith Wailoo. This book offers a compilation of medical studies and commentary
surrounding the HPV vaccine’s medical and political effects in society. The chapters focused on
in this book revolve around Wailoo’s idea that “vaccines present a locus of controversy precisely
because they offer future protection from present threats and because they depend on public fear
to mobilize citizens.”21 Additionally, these chapters outline how the vaccine debate has emerged
over time along with an unfolding controversy, with a focus on how the history of the HPV
vaccine research demonstrates the moral and ethical ideals in sexual politics. Wailoo’s analysis
of societal attitudes towards the vaccine demonstrate that there are various understandings of the
vaccine’s potential benefits that depend on the patient’s sex. The benefits differ for men versus
women due to the vaccine’s involvement with reproductive systems and sexual transmission.22
Therefore, the vaccine’s debate moves beyond the medical benefits of adolescent vaccination
and includes debates on sexual education and sexuality which is affected by parental influence
and individual morals. This paper follows arguments found in Wailoo’s work by incorporating a
parental audience response over time and comparing it to specific language from the health
agencies regarding the vaccine. This paper uses primary sources to trace the vaccine’s impact on
society over time and understand what role gender played in parental decisions to vaccinate.

Keith Wailoo, Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions.
Baltimore: Johns Hopkins University Press, 2010. 41.
22
Ibid., 49.
21
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3. METHODOLOGY OF CDC/FDA ANALYSIS
Breaking down the technical code and assumptions built into the HPV vaccine requires
an analysis of the primary source language that point to the health agencies’ prescriptions. This
analysis will demonstrate the language scientists felt should be highlighted when the public
learned about the vaccine and when doctors explained the vaccination to parents of adolescents.
Analysis and comparison of the language in the 2006, 2010, and 2016 HPV vaccine approval
press releases from the CDC and FDA offer a more in-depth view of the underlying assumptions
present from the researchers developing the recommendations and how they changed over time.
The analysis finds two main assumptions that stand out as societal ideals scientists built their
recommendations from: That the prescriptions demonstrate a greater concern for female health
and the belief that women were primarily responsible for reducing health risks of sexual activity.
4. HOW THE PRESCRIPTIONS CHANGE OVER TIME
4.1. The Assumption of a Greater Concern for Female Health
4.1.1. 2006 CDC Press Release Analysis
The 2006 CDC press release states that the vaccine is recommended explicitly for
adolescent females to protect against cervical cancer and places stress on the relationship
between HPV and cervical cancer. Cervical cancer affects solely people with cervixes (part of
the female reproductive system), and therefore this press release outlines that the HPV vaccine is
tailored specifically to the female sex. The press release states that the vaccine “is the first
developed to prevent cervical cancer due to HPV”, and that the recommendations “address a
major health problem for women and represent a significant advance in women’s health.”23 This
creates an association between the virus and cervical cancer, but it almost closes the door to
Department of Health and Human Services, & Roberts, J., “Clinical Review of Biologics License Application
Supplement – male indication for GARDASIL,” 6 (2009). Rockville. 14.
23
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associations between HPV and other cancers. This is a notable exclusion, because research in the
1990s connected HPV and anal sex. This is a key part of how the focus of the vaccine became
centered around female cancer prevention, even though the press release does state “that more
than 20 million men and women in the U.S. are currently infected with HPV.”24 This
highlighting creates the assumption that any potential association between HPV and other
ailments are inferior to the connection between HPV and cervical cancer.
The emphasis on the effects of HPV in women signals a silence of HPV’s effects on men.
The FDA’s 2006 prescription indirectly states that having evidence of the vaccine’s protections
of women’s reproductive health is enough to support the vaccine’s administration, but its impact
on male health is not. With a causal relationship being established between HPV and both
cervical and anal cancer, but only the link between HPV and cervical cancer addressed in the
recommendations, there is a greater focus on using this vaccine to protect women’s health. This
is evidenced by the fact that despite a causal link being established for both sexes, the vaccine
trials were initially conducted only on females. This idea provides evidence of the assumption
that female health was intended to be the center of vaccination against HPV.
4.1.2. 2009-2014 FDA Report Analysis
For the purpose of this analysis, the 2006 CDC press release is equivalent to 2009 FDA
Report on the research of the vaccine. This document will be compared to the language of the
scientists and researchers from the 2006 and 2016 CDC press releases to identify the technical
code focused on prioritizing women’s health. The report discusses the proposal to expand the
HPV vaccine eligibility to men aged 9 to 26-years-old. The first ideas mentioned are that the
current vaccine licensed by the FDA is for prevention of “cervical, vulvar, and vaginal cancers”,

Department of Health and Human Services, & Roberts, J., “Clinical Review of Biologics License Application
Supplement – male indication for GARDASIL,” 6 (2009). Rockville. 14.
24
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specifically related to women’s health and that this expansion would “protect men from HPV
causing genital warts.”25 This juxtaposition of the two makes it seem as if the protection from
cervical cancer offered for females and the protection against genital warts offered for males are
equivalent. This is also not mentioning the research tying HPV in males and the increased
incidence of anal cancer. Even though the CDC lists that 90% of anal cancers and 91% of
cervical cancers are caused by HPV infections, only the tie to cervical cancer was addressed in
these 2006 recommendations.26 There is an attempt to include males in the research and
recommendations but the language of equating cancer to genital wart rates is still creating an
imbalance of burden of the vaccine for one sex over the other. This is because the diseases the
report associates with female HPV infection (cancers) have greater long-term consequences than
what they identify as consequences of male HPV infection. With this written in the principles of
administration, it is placing HPV vaccination as more important for long-term health of women
than that of men, even though there is evidence to support as strong an association between HPV
and male cancers.
This brings up a burden of proof question raised by the political nature of the technology;
evidence for male vaccination after clinical trials is still not enough to place it on the same
recommendation level as there was for females. Therefore, the evidence needed to recommend
the vaccine is set lower for women even though there is similar association between HPV and
both cervical and male anal cancers. In addition, the 2010 mortality rate of cervical cancer was
25% and for male oropharyngeal cancer was 23%, demonstrating similar mortality risks between

Department of Health and Human Services, & Roberts, J., “Clinical Review of Biologics License Application
Supplement – male indication for GARDASIL,” 6 (2009). Rockville. 13.
26
“How many Cancers Are Linked with HPV Each Year?” Centers for Disease Control and Prevention, last
modified 2021.
25
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these two cancers.27 The vaccine was approved for use in men in 2010, but it is interesting to
analyze that the evidence was enough to state that the HPV vaccine was immediately approved
and recommended for females but not immediately approved and recommended for males, even
though they can also suffer from anal cancer.28
In 2014, the CDC published a Human Papillomavirus Vaccination Recommendation
update to describe the vaccines available and provide data on current research. The only section
where the gendered language enters is in the discussion of other modes of HPV prevention,
where pap smears are highlighted as a necessary means of cervical cancer prevention, even when
inoculated.29 The other sections regarding the clinical trial research for the vaccine is split
between male and female trial groups of various ages, and both are addressed as “reaping benefit
from the vaccine in order to prevent certain types of cancer.”30 However, there is prioritization of
women’s health in testing of the vaccine even when testing occurred in men. The evidence was
not enough to place it on the same recommendation level as was present for females, leading to a
burden of proof difference in the health agencies’ recommendations.
4.1.3. 2016 CDC Press Release Analysis
The gendered language in the 2016 CDC press release is completely removed, with the
CDC recommending “that 11 to 12-year-olds receive two doses of HPV vaccine…”31 There is no
longer the reference between needing the HPV vaccine to prevent cervical cancer, instead the
vaccine is deemed as “safe, effective, and long-lasting protection against HPV cancers.”32 The

“United States Cancer Statistics Data Visualizations: Cervical Cancer in Females and Oral Cavity and Pharynx
Cancer in Males,” Centers for Disease Control and Prevention, last modified 2018.
28
Department of Health and Human Services, & Roberts, J., “Clinical Review of Biologics License Application
Supplement – male indication for GARDASIL,” 6 (2009). Rockville. 14.
29
Ibid., 10.
30
Ibid., 11.
31
Center for Disease Control and Prevention, “CDC’s Advisory Committee Recommends Human Papillomavirus
Virus Vaccination,” (2016). Atlanta.
32
Ibid.
27
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first paragraph is more age focused than the previous press releases, where the recommendation
is stricter to 11 and 12-year-olds, with 15 to 26 year-olds needing an extra dose to catch up on
protection.33 There is once again this implicit assumption that receiving the vaccine at a certain
age is young people contributing to society’s future health, but the burden is no longer just on
women. There is also mention that the vaccine research was done on different age groups,
putting the focus of study of the impact of the vaccine on different age groups rather than sexes.
4.1.4. Overall Trends
Something to consider after analyzing the three primary sources is that in 2016 the
gendered language is removed from the CDC’s recommendations, but the HPV affiliated cancers
are still gendered and focused on reproductive anatomy. The main HPV-related cancers that
vaccination is outlined to prevent in males are anal and oropharyngeal cancer, both of which can
also be found in females. Although cervical cancer prevention was the initial reason given for
vaccination, over time, the emphasis on protecting women’s health over men’s lessened.
However, even as approval encapsulated all genders, the recommended guidelines for
vaccination remained different due to a less pressing causal relationship established between
HPV-related cancers in males.34 By having the causes of some HPV-related cancers tied to sex
organs, it points to a key idea in the HPV vaccine debate regarding whether vaccination is
necessary for adolescents. This is a key point of contention for parents, but it is important to note
that the press releases do not define why receiving the vaccine young is necessary.

Center for Disease Control and Prevention, “CDC’s Advisory Committee Recommends Human Papillomavirus
Virus Vaccination,” (2016). Atlanta.
34
Center for Disease Control and Prevention, “Fewer Shots Offer More Incentive to Prevent HPV Cancers,” (2016).
Atlanta.
33
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4.2. The Assumption of Female Responsibility for Sexual Health
4.2.1. 2006 CDC Press Release Analysis
The linguistic association in this report also begins to place responsibility of limiting the
spread of STDs onto females, even though offering the vaccine to their male partners would also
help females. This begins to place an assumption in society that women are responsible for the
sexual health of all and ought to take the preventive measures available to maintain health.
In the third paragraph, the CDC states that “the vaccine should be administered before
onset of sexual activity (i.e. before women are exposed to the virus), but females who are
sexually active should still be vaccinated.”35 This seems to place fault on the females for not
being vaccinated early enough when in reality, many adolescents do not have control over their
vaccination status or may not understand what they are being vaccinated against as they are
minors. As parents in most states take control of their children’s vaccination status, it is
interesting to consider how the language is catering towards the parents rather than the
adolescents. The emphasis on sexual activity points to a need for parents to take control of their
daughter’s sexual health before the children can.
The language in the next couple of paragraphs links vaccination to the need to take sexual
protection practices. The paragraphs discuss the implications of the vaccine in curbing cervical
cancer rates for women in the United States, including that the vaccine protects against 70% of
cervical cancer cases. Once again, the focus is on preventing cervical cancer, rather than HPV. It
seems that the causes of cervical cancer are entangled between sexual behavior and HPV
infection. Scientifically, HPV infections can lead to cervical cancer, but the language poses
female sexual behavior as the causal factor and therefore that the risks associated with sexual

Center for Disease Control and Prevention, “CDC’s Advisory Committee Recommends Human Papillomavirus
Virus Vaccination,” (2016). Atlanta.
35
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behavior need to be curbed before the onset of activity. This entanglement could be leading to
misbeliefs that parents had regarding how the vaccine would impact their daughters, such as it
potentially increasing promiscuity, a myth that is still linked to the vaccine today. The vaccine’s
clinical trials were also centered around finding a link between the vaccine and preventing an
anatomically female cancer, cervical. This focus on females and sexual behavior places the
burden of sexual protection on females, even though male partners could be passing HPV onto
females. The possibility of offering the vaccine to males to protect females is not addressed.
Another interesting part of the press release is that it holds the implicit assumption that
after the age of 26, women are sexually active and therefore too exposed to the virus for the
vaccine to be beneficial. This will be important to consider in the analysis of parental arguments
questioning the necessity of vaccination at a young age. The report states that “the vaccine
should be administered before onset of sexual activity (i.e., before women are exposed to the
virus)” which explicitly equates sexual activity to HPV exposure. The vaccine was said to not be
as effective after one was sexually active and potentially exposed to the virus, but placing a limit
assumes that one will have been sexually active by at least the age of 26. This points to the
immediacy of getting the vaccine before sexual activity but assumes that protection after the age
of 26 is not effective, arbitrarily setting the maximum age of beginning sexual activity.36 It is
also important to note that this paragraph makes it seem as if vaccination would protect one
against HPV, but it makes no mention of needing to institute other safe sex practices. The
vaccine would not prevent one from getting the virus, it would reduce the risk of someone
getting the infection that can develop into cervical cancer. Therefore, additional safe sex
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practices should be used in conjunction with vaccination for women, which the article does not
spell out for adolescents it is looking to attract.
This interpretation of vaccination is a crucial part of the vaccine’s technical code because
it presents the assumption that vaccination will enable women to protect their sexual health but
does not address how men can help contribute to this. The mechanism of protection is centered
around protecting women directly by inoculating them and does not address the impact of not
addressing men.
In addition to focusing on the importance of protecting female sexual health through
inoculation, the link between HPV and sexual activity is established. The paper states that HPV
is “a sexually transmitted disease and affects more than 20 million men AND women in the
United States.”37 Both sexes being affected is explicitly mentioned, but one being singled out as
more important for the regulations shifts the burden of protection onto women by stating that “by
age 50, at least 80% of women will have acquired HPV infection” with no mention of similar
statistics for men.38 This indirectly implies that women are responsible for protecting both sexes.
This assumption would produce the outcome that by having women take greater control over
sexual health, their partners benefit as well. Therefore, women are also protecting male partners
from HPV related diseases even though the latter are not stated as directly benefiting from the
vaccine. However, the reverse effect of inoculating men which would help reduce HPV rates in
women is not discussed, reinforcing the burden of sexual health protection on women.
Inoculation is not the only recommended course of action women should take to protect
their sexual health. The report also mentions that “women should continue to get pap tests as a
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safeguard against cervical cancer” after vaccination.39 Therefore, the vaccine is an additional step
in women’s health that is recommended, increasing the timeline during which women need to
start taking on responsibility of their sexual health. Women no longer need to start medical care
of their reproductive health at 21 (for pap smears) but now around age nine (for vaccination).
This is key to understand as it points to the entrance of parents in sexual health decision making.
4.2.2. 2009-2014 FDA Report Analysis
Mainly, both men and women are listed as needing the vaccine and the gender
differentiated cancers are mentioned as associations with HPV. This report was updated as
additional research trials on the risk of HPV and cancer rates in male adolescents were conducted
and the links between female sex cancers and HPV were strengthened. The recommendations
from the 2006 and 2010 reports are repeated in the 2014 report, but the latter report also offered
more in-depth information on how HPV manifests into cancer and its immunology.40 The
descriptions of the testing and the immunology of the vaccine itself are non-gendered. In the
HPV Prevalence and Incidence section, it is mentioned that research has been done equally on
men and women to analyze the vaccines seroprevalence and efficiency in specific age groups.
The descriptions of the viral transmission do address the virus being an STD and places the
burden of sexual health on both genders.
This amendment can signal a change in medical assumptions underlying the
recommendations for HPV vaccination. This change was instigated by additional medical
research being conducted, which in turn increased societal awareness surrounding the risks of
HPV as an STD. This change demonstrates that because vaccination increased over time, the
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profile of it as an STD did as well, which propelled society to want to learn more about the
vaccine’s effects and benefits. In the first few years of the vaccine’s approval for male
adolescents, vaccination rates increased dramatically compared to that of the initial years where
it was approved for females. In 2008 and 2009, 21% and 27% of females were fully vaccinated
against HPV, and in 2011 and 2012 (the first two years males could be vaccinated) 42% and 45%
of males were vaccinated. Therefore, societal action of increasing the rate of vaccination for
males and the idea that males too needed to be protected from STDs, moved some of the burden
that had been placed on females for sexual protection onto males as well.
4.2.3. 2016 CDC Press Release Analysis
Another piece that has been wiped from the report is that HPV cancer producing strains
are sexually transmitted, transmission of the virus or its classification as an STD is not directly
addressed in this release. Although, the risks of sexual activity and HPV are, the classification of
HPV as an STD is not. This is important to consider because when the vaccine was available to
only females, the idea of sexual protection was emphasized, but once the gendered division in
reception is removed, so is the direct emphasis on sexual protection. Therefore, the assumption
that sexual health is the prime reason for getting this vaccine is not as prevalent, it is more
focused on protecting overall health of society. This language is also detangling the relationship
between cervical/anal cancers and sexual activity.
Instead of simply listing the ages, the necessity of the HPV vaccine is compared to other
required vaccines for children, including meningitis and whooping cough.41 By doing this, the
CDC is implicitly saying that the HPV vaccine meets a similar threshold of importance as the
other vaccinations that almost 90% of American children receive before adulthood. This is an
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effort to increase the importance of the vaccine and potentially boost its profile to increase
uptake. This attempt to further engrain the HPV vaccination into a routine societal move is
connected to the idea that a technology eventually becomes so engrained in the needs of society
that it becomes a part of society’s identity. This is an effort to change parental behavior standards
by stating that these vaccinations are crucial for proper medical factors of society.
4.2.4. Overall Trends
The less gendered recommendation over time attempts to remove the burden of sexual
health from being solely on women, but historical work in female medicine displays that this is a
difficult idea to eliminate. Physicians Ellen Daley et al. argue that feminization of medicine has
its association with contraceptive technologies where the focus of procreative responsibility is
placed on females.42 This indirectly excludes males and other stakeholders by creating a strong
societal perception of contraception as feminine. Daley’s argument provides some support for
the claim that the CDC literature and prescription guidelines fostered a feminine view of the
HPV vaccine by the public, even though it is not itself contraception but linked to safe-sex
practices. What is interesting is that as the female centered language was removed from the
recommendations, the link between sexual intercourse and HPV transmission disappeared. This
is consistent with the assumption that sexual health should be outlined primarily when women’s
health is involved, but it is less relevant when addressing male health. This is further tying the
burden of sexual health to females.
4.3. Main points
The two assumptions outlined the cultural ideas that were then projected onto the public
for consumption and embedded in the vaccine’s rollout procedures even after the prescription
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changes. The ideas and trends in thinking pulled from this language will be analyzed with media
from society (parental blogs and magazines) to see how the changes were interpreted. It will also
be interesting to see if the social conversations from parents and media impacted the CDC
language over the years, especially as the connection between HPV and sexual activity is
removed from the CDC language over time.
5. METHODOLOGY OF MEDIA AND PARENTAL ANALYSIS
To analyze how the rhetoric has changed in the media throughout the vaccine’s
progression, this paper explores studies and magazine articles targeted to both parental and
teenage audiences. Magazine articles and advertisements for the vaccine were found by
searching through Proquest Historical Newspapers from the Claremont Colleges Library
databases. The goal was to find sources that were catered to adolescent and adult audiences, such
as The New York Times and The LA Times. The keywords used in the search for articles included
“HPV” and “vaccine” and the search date range was restricted to between January 1, 2006, and
December 31, 2021. The goal was to find articles from consistent newspaper sources in response
to the 2006 vaccine, the 2010 prescription amendments, and the 2016 vaccine change.
To explore parental concerns regarding the vaccine, articles and parental studies were
explored and compared between 2006 to 2010, 2010 to 2016, and 2016 to onward. This is
important because the HPV vaccination requires surrogate decision making from the parents, but
contrary to other child immunizations, it concerns immunizing teens that are old enough to have
views and opinions of their own. The 2006 parental decisions were found in a chapter from
Wailoo’s book, and the 2010 and 2016 parental decisions were found by searching to identify
studies conducted by medical associations.
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6. PUBLIC MEDIA TRENDS
This section will outline media perception of the HPV vaccine between 2006 to present
and analyze the content using the ideas pulled from the language of the CDC and FDA reports.
The goal is to analyze how the vaccine was portrayed to the public in newspapers and magazines
and how the rhetoric changed over time. This analysis will be used in comparison to the parental
and prescription analysis over time to identify common cultural trends that could have pushed
the prescription changes along. There are three ideas that will be focused on in the analysis: the
emphasis on the vaccine preventing cancer vs. preventing HPV, the necessity of the vaccine for
adolescents at a young age, and the vaccine’s effect on participating in risky sexual behavior.
6.1. Vaccine Preventing Cancer Vs. Preventing HPV
Over time, articles started to pivot from offering information on HPV and more towards
the focus of preventing cervical cancer. In a May 11, 2006, Los Angeles Times article, reporter
Jonathan Bor published the findings of the Merck &. Co drug trial that showed promise for the
vaccine to be approved by the FDA in the following months. The article provides numerical
evidence of the vaccine’s effectiveness in protecting against HPV and includes quotes from
experts in the field that echo the original Gardasil advertisement message that vaccination is
needed for one to be a reasonable member of society.43 For example, gynecologist, Dr. Gene
Rudd, states that the vaccine is important because “where there are diseases, the only reasonable
way you can protect individuals and society is to be immunized.”44 This echoes the idea that
getting the vaccine would make one a reasonable member of society, similar to the language
used in the 2016 CDC report where getting the HPV vaccine was compared to getting other
commonly accepted vaccines such as Tdap.
Jonathan Bor, “Young Girls could be in line for Vaccine to Stop Cervical Cancer,” Los Angeles Times A.10
(2006).
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After this article was published, Vogue magazine started including page-long Gardasil
advertisements in December 2006 that offered educational information and pushed for parents
and daughters to ask their doctors for the vaccine. The first issue included scientific information
connecting cervical cancer prevention to Gardasil and pushed girls to talk to their doctors about
receiving protection, but did not offer information on how to protect themselves from HPV
through sexual transmission.45 The advertisements were different in each Vogue edition, but
most stated a version of the following message: “the HPV vaccine can protect against cervical
cancer in the future” without offering a description of HPV transmission or offering other
resources to get information surrounding protection against STDs.46 An example of a Vogue
advertisement is seen in Figure 2.47
Figure 2.

Figure 2. This shows an advertisement for the vaccine in a 2006 edition of Vogue.
Source: “Advertisement: Gardasil,” Vogue 196, no. 12 (2006). New York.
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On February 28, 2007, reporter Denise Gellene from the Los Angeles Times followed up
on Johnathan Bor’s article that offers even more statistical information pertaining to the lowered
risks of cervical cancer for women between the ages of 14 and 29 years old. The article also
offers information on where women could get more educated on the disease and the vaccine,
particularly because of how common the infection was and how fast it was becoming a political
rather than medical debate following the FDA approval.48 From this article, the focus of the
vaccine was to prevent future cancer cases, not in reducing HPV cases. This jump from not
including information regarding sexual transmission and information on what HPV is, is similar
to that found in the 2010 and 2016 prescription languages. In addition, mention of the vaccine
protecting against a sexually transmitted disease decreased over time. By having increasing
cervical cancer rates as the vaccine’s focal point for the vaccination campaign, there was an
unbalanced burden on women to protect sexual health, as seen in the language analysis above.
6.2. Necessity of the Vaccine
Another common theme in popular media between 2006-2016, is proving the necessity of
the vaccine, especially for women to be socially responsible individuals and protect society’s
future health. As stated above, obstetrician-gynecologist quoted in the 2006 Los Angeles Times
article, Dr. Gene Rudd, expresses that “the only reasonable way to protect individuals and
society from diseases out there is to be immunized.”49 This article details that societally
responsible individuals are vaccinated and demonstrates how doctors advertised the necessity of
the vaccine to parents. The articles show that over time the reasons for offering men the vaccine
extended past protecting women, but also protecting themselves and future partners.
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One concern regarding the necessity of the vaccine was that parents were unsure as to
what the vaccine would accomplish, considering that yearly pap smears were still recommended
for women. The articles were working to make sure that parents taught their daughters that pap
smears were still the best method of preventing progressive cervical cancer cases. In an article
from The Women’s Health Activist, Dr. Fugh-Bergman and Dr. Massion described that the
vaccine lowers the risk of getting HPV and abnormal pap smear results which means that women
would be less likely to need a procedure to remove the abnormal cells.50 This procedure could
increase the risk of a woman having a premature birth later on, echoing Merck’s advertisement
message that getting the vaccine makes women societally responsible individuals for current and
future generations. Therefore, the pap smear does still offer the best detection of progressive
cervical cancer, but the vaccine helps to reduce needing cancerous cell removal procedures.
As more discussion occurred, more articles regarding male vaccination were being
published. In 2009, the topic of male vaccination became more mainstream because Merck &
Co. started conducting randomized control vaccination trials to gain approval for Gardasil use in
adolescent males. A 2009 article from Seventeen magazine echoes this call for educating girls
about potential risks of not getting vaccinated due to the possibility of getting the virus from any
kind of sexual relations. Without using lots of numbers or complicated scientific language, the
article offers educational resources for readers and encourages them to share them with their
parents, tying in the surrogate decision-making idea.51 The push for male vaccination became a
topic of women’s health as well, and a Winter 2010 edition of Ms. magazine echoes calls for
HPV vaccination to be in effect for men as the virus can travel between partners through skin
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contact and can be transmitted through all kinds of sexual contact; circumstances and the sex of
the partner did not matter.52
Following the male HPV vaccine’s FDA approval, the rhetoric surrounding the vaccine’s
benefits for both genders did not change much. On October 26, 2011, Los Angeles Times reporter
Shari Roan wrote that the vaccine has been shown to protect against HPV strains leading to anal
cancer and that this 2011 change serves to equalize the burden of vaccination to both sexes.53 A
November 1, 2011, Los Angeles Times article offered more of an educational report. Here the
FDA approval is defined, and the idea of HPV causing genital warts in both genders is
mentioned.54 Therefore over time the articles demonstrate that necessity of the vaccine became
extended past the need for women protecting themselves and their future families and included
men protecting themselves and their potential partners.
The link between HPV and other types of cancers started to get increased media attention
over the next few months, as shown in a November 2011 USA Today, Farmingdale article. The
reporter tries to extend the discussion of HPV to other kinds of cancers, including anal and oral
cancers that predominantly affect men. Pushing for greater vaccination from parents and children
by demonstrating an increased benefit from receiving the vaccine, increasing its necessity.55
Reporter Karen Kaplan from the Los Angeles Times on February 10, 2015 echoed this same
rhetoric surrounding the importance of vaccinating both genders because of the evidence
connecting HPV to cancers that can afflict all bodies. She admits that HPV can lead to more than

Adina Nack, “Why Men’s Health Is a Feminist Issue,” Ms.: Arlington 20, no. 1 (2010).
Shari Roan, “Routine HPV vaccination is recommended for boys,” Los Angeles Times A.1 (2011).
54
“HPV Vaccine for Boys? Yes,” Los Angeles Times A.16 (2011).
55
“HPV goes Beyond Cervical Cancer,” USA Today: Farmingdale 140, no. 2798 (2011).
52
53

28

Jammes 29
just cervical cancer, but penile, anal, and oropharyngeal cancers, which is then followed up with
the emphasis on helping both boys and girls.56
Following this discussion, 2016 media demonstrates when necessity of the vaccine for
men started to take off. For example, a July 13, 2016 article from TeenVogue targets adolescent
boys and is raising awareness on campaigns pushing males to get the vaccine, assuring them that
it does pertain to their health, not just female health.57 This article is also pushing the idea that
teens should take control of their health, and not assume that if the vaccine was necessary, their
doctors would have already given the shot.
Another way necessity was advertised after 2016, was by catering specifically to
adolescents and pushing them to have a more overall health benefit approach to evaluating
vaccination. An April 2017 edition of Girl’s Life offers a couple accounts of young girls that
contracted STDs through unprotected sexual interactions, not just intercourse.58 The goal is to
push girls to talk to doctors and parents about getting tested and having a healthy conversation
with partners before having intimate contact with them. This article offers an increased pool of
risk in getting HPV, increasing its potential causes and telling adolescents that this vaccine can
help in more unprotected situations. A similar article was published in the October 2016 issue of
Men’s Health that calls for parents to get their children vaccinated early to protect their future
health, much like one recommends their children not to smoke or drink too much. It uses parental
logic to draw comparisons between situations: it is something else one can do to better their
health now for a better future, like not partaking in certain risky activities.59 This article wraps up
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the connection between increased necessity of the vaccine, the idea that vaccination is a benefit
to society, and that vaccination represents rationality of the individual.
6.3. The Vaccine and Risky Sexual Behavior
Another common thread throughout popular media regarding the HPV vaccine was an
effort to dispel rumors that the vaccine led to an increase in risky or “taboo” sexual behaviors. In
the April 24, 2007, edition of The Advocate, reporter Morgan Kroll addresses the importance of
vaccinating boys, “not only to protect women but to protect them from anal cancer risks.”60 It
also acknowledges that Merck was in favor of pushing for this approval, but primarily because it
would get them increased revenue, even though approving it for pre-sexual boys who were at
risk of contracting it through anal sex would be “more controversial than the female approval is
already.”61 This article demonstrates how the discussion surrounding male vaccination and
sexuality was a topic of concern for parents at the time and that it was a reason given for why
boys may not have been approved for vaccination early on.
Another common idea found across HPV vaccine articles in 2007 surrounding sexual
behavior is debunking the myth for parents that the vaccine increases sexual promiscuity. An
October 2007 article of USA Today, Farmingdale explains a study that debunks misinformation
that getting the HPV vaccine causes girls to engage in more sex than unvaccinated females. This
follows studies that 10% of parents were concerned that vaccinating their young daughters would
encourage them to have more sex.62 The goal here is to present scientific information catered to
parents to put them at ease and prove that science does not support the idea that vaccination
increases sexual risky behavior of the patients.
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In a March 2016 Cosmopolitan magazine article, reporter Katherine Schreiber pushed for
women to not be ashamed to discuss STD protection with their partners, although the article is
focused on heterosexual relationships. This article is framing women as needing to be vaccinated
to protect against infection from any kind of sexual activity, stating that “strains of HPV can
easily pass on the infection to pretty much anyone they go down on, make out with, or decide to
have sex with sans condom.”63 This flips the concern around by stating that sexual practices are
less risky with the vaccine, but the vaccine itself does not implicitly drive an increase in risky
sexual behavior. In fact, the article discusses that the vaccine should be given to men and pushes
women to talk to their partners about being vaccinated, both of which could lead to safer sexual
relations. This connects to the idea of the necessity of the vaccine but also points to sexual
behavior being considered risky if unvaccinated, whereas the vaccine itself would not increase
sexual behavior, just make current relations safer. Therefore, the article demonstrates that over
time all genders were pushed to get the vaccine to protect themselves and others from the risk of
HPV from any kind of sexual interaction.
6.4. Trends Over Time
After 2017, there were a couple more teen magazine articles published but as time went
by, media regarding the vaccine has been more concentrated in educational campaigns from
medical associations or international organizations that aimed to bring a more international scope
to HPV vaccination. This was due to the decreasing rate of cervical cancer cases in the United
States compared to less wealthy countries.
The article research also pointed to the discussions regarding the HPV vaccine in teenage
magazines increasing after 2016, while its discussion to more adult audiences plateaued. This
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could be due to many factors, including the rapid increase in social media influence. However, it
does point to a shift in the audience for HPV vaccination campaigns and educational pamphlets
because now periodicals were focused on giving the information to the patients rather than
convincing the parents to accept it for their children. This shift in audience is also mirrored by a
shift in the information presented, because the more recent articles focus more on the importance
of safe sexual practices, although still heterosexually focused. However, the scientific facts and
previous studies were more expanded upon when the parents were the main audience and
periodicals and women’s magazines were the medium. Overall, the three themes detailed above
offer a picture of how popular media framed the vaccine to the public and expresses what media
believed was most important to note in response to the vaccine’s prescriptions over time. These
trends will be important to consider when looking at parental concerns to see if the concerns over
time mirrored the common threads found in the government language and popular media.
7. HOW DID THE PARENTAL RESPONSE CHANGE?
Analyzing the parental response to the HPV vaccine throughout time is important
because adolescent vaccinations require surrogate decision-making and the parental ideals feed
into the opinions of their children. There are three main common concerns from parental blogs
and clinical studies within the studied time frame: questions of the vaccine’s necessity, the
relationship between HPV and sexual behavior, and distrust in science.
7.1. Questions of Necessity
Similar to how media tackled the question of necessity of the vaccine, this was a main
parental concern that lessened over time as men became accepted into the vaccination pool. A
study of parent’s vaccine decisions was conducted by scientists Karen Noakes et al. in late 2006
that included in-depth interviews of 20 American mothers and one father who all expressed
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interest in modifying existing compulsory vaccination schedules for their children.64 As the
vaccine protects against strains of HPV that are primarily transmitted through sexual contact,
these parents expressed that they do not see the necessity of such a vaccine for young
adolescents. One mother was described in the study as “wanting to seek out the vaccine for her
11-year-old daughter eventually but felt that it was currently unnecessary since her daughter was
not yet interested in sex.”65 Parents in this study demonstrate the assumption that the vaccine is
needed only right before sex starts, not years before, but possibly even that the vaccine would not
offer much of a difference to an adolescent’s health. Some of these parents also expressed
concern that by giving their daughters the vaccine, it removes a potential tool for teaching
responsibility which as parents, they believe is their job.66 This created a tension between
vaccination campaigns and parents as it raised concern that parental duties were being
encroached upon.
In the midst of this study’s result, there have also been some pro-vaccine conservative
family groups like Focus on the Family who endorse teaching abstinence until marriage as the
best practice against STDs but also acknowledge the risks of getting HPV from nonconsensual
relations. The group stated in 2006 that “HPV infection can result from sexual abuse or assault
and that a person may marry someone still carrying the virus. This provides strong reasons why
someone practicing abstinence may benefit from the vaccine.”67 Even some groups that found
the vaccine at odds with their spiritual beliefs had found necessity of the vaccine, which added to
the controversy among parental communities.
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Merck & Co. was the initial producer of the HPV vaccine, Gardasil-4, in 2006. The
Merck & Co. television advertisement published in response to the 2006 FDA approval had three
parts: One Less, Make the Connection, and Tell Someone. Since girls were the only ones
approved to receive the original vaccine, the advertisement focused only on girl’s bodies being at
risk of HPV. Funded by Merck & Co., this advertisement framed Gardasil as a cancer risk
reducing vaccine, not as one preventing an STD that could manifest into cancerous cells. This
was potentially to reduce the skepticism and assumptions surrounding STDs. The third part of
the advertisement campaign is “Tell Someone” where the goal is to pay the information forward
and to arm individuals with the moral, political, and public health leverage that could increase
protection against cervical cancer in society.68 In some versions of the print advertisement, the
taglines include “Ideal girls make the right choices” and “The Power to Help Prevent Cervical
Cancer is in Your Hands and on Your Daughter’s Arm.”69 This last piece of the campaign
includes mothers and the idea of surrogate decision making in the public discussion and also
makes assumptions that to be an ideal member of society, girls should get the vaccine and
mothers should push their daughters to make “the right choice.” This ties to the talking point that
to be vaccinated is to societally responsible.
Past debates regarding other contraception technologies, such as condoms and Plan B
pills have had similar arguments regarding the idea that increasing access can lead to an increase
in sexual behavior.70 This is especially important in the HPV vaccine debate, where parents did
not see the link between HPV and cervical cancer prevention as pressing in adolescence. The
impact of HPV and sexual behavior was more glaring, leading parents to thinking about teaching
“HPV – Tell Someone,” Merck & Co., Inc, last modified 2006.
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abstinence rather than vaccination for protection. In a 2014 study, researchers surveyed a sample
of 1,504 parents of adolescents between the ages of 11 and 17 years old and 776 physicians to
identify what kind of messaging would persuade parents to push for their children’s vaccination
and what information physicians would prefer offering their patients’ parents. The result found
that the most popular message was “this vaccine can prevent cancer in the said child.”71 65% of
parents were receptive to the message and 69% of physicians found it the most persuasive to
offer parents and this was not affected by the parents’ race, education, or child’s sex.72 Shorter
messages that identified the link of HPV and cancer, especially cervical cancer, had the greatest
beneficial results in pushing parents to vaccinate their children, whereas mentioning sexual
behavior and transmission risks did not reap as favorable results.73 The strength of the language
was also important in pushing for vaccination because it demonstrated greater confidence the
doctor had in the results of the vaccine. These results are reflected in the changed prescription
language between 2006-2016. The study also showed that emphasizing the direct link between
cervical cancer and HPV prevention and pointing out that the vaccine could yield fewer future
abnormal pap smears best translated the necessity of the vaccine.
It should be noted that parental concerns surrounding the necessity of the vaccine at a
young age was not addressed beyond the FDA statements that “vaccination should occur before
the onset of sexual activity.”74 This continues to be a parental concern now as health agency
language and popular media have not given more reasons for the proposed age of inoculation.
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7.2. Relationship between HPV and Sexual Behavior
Concerns regarding the potential for the vaccine to increase sexual promiscuity in young
females was another prominent theme among parents. As demonstrated in section 6.3., much of
popular media aimed to demonstrate the importance of taking sexual precautions even if one was
not partaking in sexual practices and towards disproving the myth that the vaccine would lead to
an increase in risky sexual behavior. In Karen Noakes et al.’s study, the parents believed that
their daughters were better off learning responsibility from safe sex or abstinence practices
instilled upon them from their families and that sexual health is tied to morals that parents should
instill.75 If their daughters were to get the vaccine, parental power to teach sexual protections
could decrease, which parents felt could increase sexual behaviors that could lead to “unwanted
consequences.” This risk pushed parents to doubt the vaccine, especially if pap smears could
detect cancerous cells and the fact that cervical cancer would not develop for decades.76
In 2016, the National HPV Vaccination Roundtable and Vaccinate Adolescents Against
Cancers program convened two national meetings at the American Cancer Society. The goal of
these meetings was to identify how to communicate to parents about the HPV vaccine to increase
vaccination uptake through catered messaging online and through physicians. A main worry was
that the disease it was protecting against was sexually transmitted, whereas abstinence could
have a similar protection effect without requiring inoculation.77 The study shows that main
concerns in the parental community have stayed constant since 2006, but vaccine safety has
increased in influence compared to the previous common concerns between the vaccine and the
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risk of increasing sexual promiscuity. The study ties this increase to the rise of anti-vaccination
rhetoric through social media, creating increased skepticism in parental communities.
This study outlined changes that were made to parental communication, such as the need
for doctors to adopt gender neutral language when recommending HPV vaccination to parents to
lower the connection between the vaccine and sexuality or promiscuity.78 This is similar to how
the FDA changed the language between the 2010 and 2016 prescriptions. This is especially
important considering that cervical and anal cancers are two of the most prevalent cancers
stemming from HPV infections which have been linked in the media to sexual promiscuity for
females and sexual relations between men. A topic that has gained prevalence in parental
concerns over time is the rise in government vaccination mandates to attend public school, an
idea that continues in court battles today and has increased concerns over parental autonomy.
7.3. Distrust of Science
Another common theme among these parents is that they see the HPV vaccine campaign
as a large marketing push, and therefore lowering the medical value of the vaccine. This concern
stems from the fact that the vaccine was heavily marketed by its producer at the onset of its FDA
approval.
As mentioned above, in 2006 Merck & Co. created a three-part television campaign
focused on framing Gardasil as a risk reducing vaccine from cancer, not as one preventing an
STD that could manifest into cancerous cells. This was potentially to reduce the skepticism and
assumptions surrounding STDs.
The “One Less” campaign starts by clearly outlining that by taking Gardasil, girls would
be “one less” person at great risk of developing cervical cancer and that it is their responsibility
as individuals to take on this vaccine to protect themselves and society. The advertisement
78
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presented adolescents from diverse backgrounds saying the tagline and pushing the vaccine as
the right tool for protection from cervical cancer, rather than from consequences of unprotected
sex.79 The film advertisement presents the vaccine as empowering for women as it protects them
from future risks of cervical cancer and their future families, because it pushes them to take care
of their reproductive systems young. They are therefore making their bodies “less risky” by
empowering themselves with both knowledge and biological protection.80 One key piece of this
campaign is that it does not mention HPV as the main target of the vaccine, but cervical cancer,
which brushes over the idea of protection against an STD, like how popular media did in 2006.81
This advertisement also emphasized the binding of a mother and daughter by showing images of
the girls getting vaccinated in a family unit, but does not allow for sexuality to be explored.
The second part of the TV Public Service Announcement and Advertisement campaign
from Merck & Co. was titled “Make a Connection.” The goal here was to tell stories of survivors
of cervical cancer and connect women together through their risks of developing the disease due
to their reproductive bodily similarities.82 These campaigns also used celebrities, such as Eva
Longoria, to get a stronger connection between women across all races, as all women had equal
risk of getting HPV. The goal of this advertisement was to open conversations of vaccines and to
make the risks of HPV more widely known so that the vaccine could be seen as pertinent to
women’s lives. However, one noted idea parental communities noticed from the first two pieces
of this advertisement was that Merck & Co. attempted to demonstrate an idea of unity amidst all
women to get the vaccine but not all women had the same resources to access the vaccine.
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Therefore, parents felt that the marketing brushed over the financial impediments to getting all
doses of the vaccine, making the vaccine seem profit driven instead of focused on protecting
girls.83 The conversation was now to reduce the risk of cervical cancer by way of HPV, and that
cervical cancer risk is what connects women together, not the risk of HPV.
This marketing push feeds into the third common concern among these parents: that the
review and development process of the vaccine was more profit than medically driven, causing a
distrust of science. One mother compared the HPV vaccine as if she would be “putting birth
control in [her] child’s orange juice, just in case.”84 Another parent expressed “[she felt] things
are rushed through so fast to get on the market without due diligence done in safety testing.”85
These campaigns made up the first Gardasil advertisement and increased public
awareness of its availability, and its taglines became associated with the vaccine in the future as
well as became infused with perceptions of the illnesses the vaccine protects against. However,
the campaign did not address sexual protection or the possibility that males can use the HPV
vaccine to not only protect women from risks of cervical cancer but also themselves from other
cancers, similar to what the FDA language lacked in 2006. By focusing on females, the
advertisement is placing the burden of health care protection on females, similar to how the FDA
language in the 2006 report did. Sexuality is also not mentioned in this campaign; by excluding
other members of the population, it is insinuating that women are the only ones at great risk of
catching cancer-causing HPV. This countered articles at the time that were pointing to males
benefiting from HPV vaccination, causing confusion among parents and adding a layer of
distrust of the information that was being put forth.
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Another important absence from the advertisement, notably in the “Make a Connection”
piece, is the differing accessibility to the vaccine depending on one’s race or income levels. The
advertisement pushed for all women to get the vaccine and showing that all women have the
same risk of getting HPV but did not mention that access is not the same across all women. The
advertisement also did not offer resources women can use to find a provider and did not address
that not all women have equal abilities to get the vaccine, especially given its 3-dose schedule (at
the time) and high price tag. This focus on just pushing the vaccine, and not offering resources
for differing communities demonstrated a lack of awareness from the company regarding
accessibility. This advertisement feeds into the large marketing campaign that surrounded the
HPV vaccine, and since they were pushed by the manufacturers, parents took to seeing the
vaccine as more of a marketing stunt. This fed into their concerns around distrusting science
because it was coming from a source who would be making a profit from vaccination.
7.4. Overall Trends
Overall, some parental concerns change slightly over time, especially towards the
necessity of the vaccine, but others such as distrust of science and the link between vaccination
and increased promiscuity have continued from 2006-onwards. These trends are like those found
in the analysis on CDC/FDA language and the focus of the vaccine in popular media. This
demonstrates that over time, especially with the acceptance of male vaccination, the vaccine has
been shown to offer adolescents greater long-term benefits than risks.
However, the intersection between HPV’s transmission and some parental concerns
regarding sexuality have continued to permeate, even as CDC/FDA language has moved away
from designating HPV as an STD and towards it being just a pre-cursor to cancers. These
concerns regarding the possibility of the vaccine instigating promiscuity are centered around
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daughters, which fits the themes pulled out from the CDC/FDA language that sexual health is
centered around females, even if a larger proportion of males carry the virus. With the HPV
vaccine being approved in 2006 for females only, this centered the arguments for and against the
vaccine around female health, to a point where even when male vaccination came to fruition, it
was mainly to protect women.
8. STS DISCUSSION
Overall, analysis regarding the HPV vaccine over the last 15 years demonstrates two
main assumptions within the vaccine’s recommendations. The assumptions that women’s health
requires a lower burden of proof than men’s and that women need to take responsibility for the
sexual health of society are embedded within the regulations, forming the technical code.
Although the burden of women’s sexual health changed in 2016, the former underlying
assumption impacting the importance of women’s and men’s sexual health still presents itself,
both in public media focus and in parental concerns. This study does not conclude why parental
concerns were focused on what they were and whether these ideas are causing lower than
expected vaccination rates, but they do point to dissonance in communication between scientists
and parents.
The ideas pulled out from popular media and medical reports line up to concerns
stemming from questions due to the CDC/FDA language, but parental concerns do not. The
connection between vaccination and promiscuity is not addressed in the original language, even
the relationship between HPV and sexual transmission is limited and removed over time.
However, it has been a main parental concern surrounding the vaccine over time, especially
revolving around female promiscuity. This points to a key cultural effect between the vaccine’s
initial focus on women and how it was translated to parents.
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One key part not addressed by the debate is how transgender patients are viewed in this
discussion. The earlier CDC and FDA prescriptions state gender as a binary construct, whereas
the 2016 update solely states adolescents as a communal group. The impact that this cervical
cancer focused discussion had on transgender individuals with cervixes is not addressed and is a
topic to analyze in future research.
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9. INTRODUCTION TO COST-EFFECTIVENESS
As pointed out in section seven, distrust of the vaccine due to its marketing was
prevalent, especially with the vaccine being sold at a record high price for an immunization. To
best understand parental concerns, this section analyzes whether obtaining the vaccine is costeffective in reducing cancer cases and their associated costs. This section of the paper will
explore the economic effectiveness of vaccinating adolescents against HPV at the 2018 rate, as
well as the effectiveness of fully vaccinating individuals using a present discounted value model.
I will analyze if the marginal cost of every full set of the vaccine (two-dose) administered to
adolescents outweighs the marginal benefit it offers to those receiving it. The marginal cost will
be defined by the sum of average market price of full vaccination and the marginal benefit will
be defined by future health care and mortality costs prevented.
The above values will be defined using established literature and publicly available data
regarding rates of vaccination, the average age associated with the onset of cancer, and the rate
of return provided by vaccination. Calculations will be conducted for both men and women, as
they have different associated illnesses from HPV, and will be estimated for vaccine
administration ages ranging from 13 to 17 years of age. The model will use the HPV vaccination
rate data from the CDC’s annual teen immunization surveys between 2008 and 2018, and the
current literature in section 10 will define the other pieces of information that will be calculated.
Present discounted value calculates how much the cost of medical expenses or mortality a
certain period in the future is worth in today’s dollars. To define the cost of loss of life due to an
HPV associated cancer, this model will use the income approach.86 This approach will be
detailed further in section 11, with the goal of quantifying a human life using the estimated value
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of labor income that the deceased would have earned over their remaining lifetime had their
untimely death not occurred. Economically, this model allows for analysis of whether the
campaign to offer every adolescent a two-dose HPV vaccine is cost-effective in preventing
associated cancer cases and fatalities. The analysis aims to answer the policy question of whether
funding should be geared towards the administering this vaccine or other health care measures,
such as providing payment for cancer treatments or different safe sex education programs.
This question is important to analyze for two reasons: the decreasing trends in United
States associated cancer rates and the vaccine’s high price. In other words, is the high price of
inoculation justified if cancer rates are falling before the vaccine’s effects have kicked in?
A. Falling Cervical and Oropharyngeal Cancer Rates: Over the past two decades,
cervical cancer case and death rates have decreased, with the rate of new cases falling
from 8.0 per 100,000 women in 2007 down to 7.0 per 100,000 women in 2018.87 In
parallel, the cervical cancer death rate fell from 2.6 per 100,000 women in 2007 down to
2.2 per 100,000 women in 2018.88 Thus, despite the vaccinated population being too
young to have received the vaccine’s benefits, cervical cancer rates and fatalities have
decreased. As rates have decreased before the vaccinated population has reached the
average age (mid-forties) at which women are diagnosed with cervical cancer, the
question of whether the campaign is cost-effective, and whether this campaign is the best
way to continue this downward trend, becomes pertinent. Oropharyngeal cancer rates in
men have gone from 17 cases per 100,000 men in 2007 to 18 cases per 100,000 men in
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2018.89 Oropharyngeal cancer death rates in men have stayed stable at 4 deaths per
100,000 men between 2007 and 2018.90 Thus, it may be the case that the HPV vaccine
would fail a cost benefit analysis for one sex (female) but pass for the other (male).
B. Substantial Vaccination Cost: The vaccine’s average price tag of $192.61 (with either
private health insurance or Medicaid) per dose, even though prevention screening is still
recommended with inoculation, potentially makes the vaccine inaccessible to lower
income individuals. This begs the question of whether funds should be steered towards
different uses, such as different sexual education, birth control alternatives, or research
towards treatment of other fatal diseases.
The cost-effective analysis will continue like so: I will summarize the current literature
on economic costs and benefits of the HPV vaccine to society. I will then provide background on
the vaccine’s protection rates, explaining how the research fits in with current literature while
offering a new perspective on the issue and describing the method and data used to explore the
research question. I then demonstrate the calculations and results of the analysis, provide a
conclusion on the findings, and offer potential avenues for future research.
10. COST-EFFECTIVENESS LITERATURE REVIEW
The established literature this paper examines is categorized into five different
subsections: Studies informing how to utilize the present discounted value model, studies on
calculations of the value of a human life, studies analyzing cost-effectiveness of different
policies for HPV vaccination in the United States, studies analyzing the cost-effectiveness of
HPV vaccination for men, and studies analyzing the HPV vaccine’s cost-effectiveness outside
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the United States. The papers in each of these categories will help provide and calculate
assumptions for missing information in the model.
10.1. Present Discounted Value
In their article, Baudouin Standaert et al. outline how to assess the economic value of
vaccinations based on the different stakeholders involved in policy decision making.
Traditionally, cost-effectiveness analysis has been used to calculate the incremental costeffectiveness ratio (ICER) to assess whether extra payment for a health benefit obtained is good
value for the price from the perspective of the payer.91 Previously, vaccines have been evaluated
in terms of whether they reduce risk for losing quality-adjusted life-years (QALY). In earlier
studies of vaccines, price erosion (consistent loss of price over time) occurred in a short period of
time. However, this has not been observed in newer vaccines, particularly for HPV, because
modern vaccines feature more complex research and development processes. Thus, a more
dynamic model of cost-effectiveness should be used for modern vaccines.92 The fiscal health
model of present discounted value used in Standaert’s study analyzes the economic value of a
vaccine that does not produce benefits for a delayed period.
10.2. Statistical Value of a Human Life
Calculating the statistical value of a human life is necessary for analyzing whether the
cost of inoculation is lower than the costs of loss of life from cancers the vaccine would increase
protection against. In their paper, Steven Landefeld and Eugene Seskin, detail two methods of
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calculating the value of a human life, the human capital and adjusted willingness-to-pay
approaches.93
The human capital approach assumes that an individual’s life is measured by future
production potential at present discounted value, where the net loss to society of an individual’s
death is the difference between one’s earnings and consumption expenditure. This approach
contains two limitations: There is strong sensitivity to different discount rates and reliance on
income to determine one’s value, which gives unemployed and retired individuals a zero value.94
The willingness-to-pay approach attempts to rectify some of these limitations by using
principles similar to the potential Pareto improvement principles.95 This model determines what
a population at risk is willing to pay for small reductions in the probability of their death while
including measures for non-labor and labor income, value of leisure, and aversion to risk.96
Ideally, proper calculations of the value of a human life use relevant income and nonmarket measurements but labor earnings are the only readily available measurement by age and
sex. Therefore, this paper will follow the human income approach to putting a value on a human
life. In particular, this study uses the disposable personal income of the average individual fitting
the model’s characteristics to measure the value of a life.
A paper that conducts a model regarding the impact of treatment over future cases of an
illness is Robert Brent’s. In his paper examining life expectancy in nursing homes, Robert Brent
uses a value of statistical life model that informs how this paper’s model will calculate the value
of lives lost to the examined cancers. Brent tests whether nursing home residents being sicker
leads to lower survival rates of dementia patients in nursing homes. He finds that the value of
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lost years of life per individual living in a nursing home is $1.7 million per person.97 This
number is based on labor market data, takes an equity approach using a 3% discount rate, and
uses remaining life expectancy in years to estimate the value.98 This paper is useful to
contextualize the value of a statistical life approach that this HPV study will take on to measure
the significance of life lost to the studied HPV-associated cancers.
10.3. Cost-Effectiveness Inside the United States
To analyze the potential benefits of the vaccine, one need first place a numerical value on
the medical costs attributable to HPV cancers. In their paper, Harrell Chesson et al. examine
estimates of the direct medical costs attributable to HPV to illustrate the potential benefits of
vaccination.99 They find that the medical cost burden of preventing and treating HPV-related
disease in 2010 was $8.0 billion, $0.4 billion of which was for treating cervical cancer, $0.3
billion of which was for treating oropharyngeal cancer (OPC), and $6.6 billion of which was for
screening and follow-ups (not including vaccination costs).100 The authors used pap smear
incidence and cost data from Kaiser Permanente Northwest and the National Breast and Cervical
Cancer Early detection Program and cost of cancer treatment data from private medical claims
data.101 As $6.5 billion was associated with follow-up costs of cervical cancer screening, the
authors conclude that HPV vaccination could be cost-effective in removing some of these
follow-up costs due to its high success rate. Chesson’s paper offers numerical estimates of cancer
treatment costs that can be used in this model, though this paper will not directly replicate
Chesson’s effectiveness calculations.
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In her article, scientist Partha Basu notes that HPV vaccine clinical trials demonstrate that
the cervical cancer prevention strategy with the lowest incremental cost-effectiveness ratio per
QALY is combining HPV vaccination at age 12 with triennial conventional cytologic
screening.102 This offers a baseline estimate of cost-effectiveness, but the article also mentions
that this result could change due to price and this is something that this present HPV study will
explore further. Basu’s article was published prior to the acceptance of the 9vHPV vaccine that
will be used in the present study, meaning that the calculations that will be conducted will
provide updated results for cost-effectiveness. A useful part of Basu’s paper was that it offered
different sources that will be examined later in the paper and vaccination efficacy values that are
used in this model.
In a separate meta-analysis of the cost-effectiveness of HPV vaccination in the US,
Joshua Pink evaluated the economic models that have been performed to address this theory. A
key result of the analysis was that the new 9vHPV vaccine (which incorporates a larger number
of strains), has been shown to be more cost-effective than the previous two HPV vaccines
available in the United States.103 This sentiment is echoed by David Durham et al. in their study,
where on the national level, the 9vHPV vaccine was cost-effective compared with the previous
bivalent and quadrivalent vaccines, despite the higher cost per dose.104 Durham et al. takes their
analysis a step further to state that the expansion of coverage would have the greatest health
impact in those states with the lowest coverage due to the decreasing marginal returns of herd
immunity. In fact, the study deduces that with 9vHPV, coverage would reduce incidence by 73%
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and mortality by 49% compared to equal vaccination rates with the previous two vaccines and
would yield 65,000 QALYs.105 The study also finds that universal HPV vaccination coverage in
the United States would be cost-effective at a willingness-to-pay of $159,000 per QALY. These
studies not only provide insight into the benefit of using modern HPV vaccine data where only
the 9vHPV vaccine is available but offer a benchmark for which to compare the data and model
results from this study.
In a cost-effectiveness study between the three types of HPV vaccine that have been
available since 2006 (bivalent, quadrivalent, and 9-valent), the 9-valent vaccine has been deemed
as the most cost-effective version of the HPV vaccine.106 The study showed that the quadrivalent
vaccine was more cost-effective and medically effective in protecting against HPV related
cancers than the bivalent vaccine was.107 A 2016 UK study found that the incremental costeffectiveness ratio of quadrivalent vaccination was found when a QALY is valued at £30,000
with its main benefit found in preventing anogenital warts linked to HPV strains 6 and 11.108
During a 20-year study comparing cross-protection against HPV between the vaccines, the 9valent vaccine had a cost per QALY of $12,208 compared with a $15,528 cost per QALY for the
quadrivalent vaccine.109 However, the price difference needed to be negligible in these studies,
something that did not occur in 2016 when the 9-valent vaccine was rolled out in the United
States.110 This detail is not addressed in current time as the medical community has deemed the
quadrivalent and bivalent vaccines no longer comprehensive HPV vaccines for adolescents, and
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the 9-valent vaccine is currently the only HPV vaccine available in the United States. An
additional factor that was not addressed in this comparative study, is that the dosage schedule for
the new 9-valent vaccine is two rather than the previous three doses needed under the
quadrivalent and bivalent vaccines, cutting the overall cost of vaccination.111
Another study informing how to determine health and economic outcomes of vaccinating
a population was conducted by Jane Kim and Sue Goldie. In this study, demographic data of preadolescent females in the United States was used to determine health outcomes after vaccination.
The results found that the vaccine was beneficial in averting other HPV-related cancers, genital
warts, and juvenile-onset recurrent respiratory papillomatosis. The study also found that under
the assumption that the vaccine provided lifelong immunity, the cost-effectiveness ratio for a 12year-old female was $43,600 per QALY gained. This is compared to the practice of just
screening for cervical cancer, and it is important to note that this study analyzed the effectiveness
of the older vaccine that is no longer used in the United States.112 By examining the effects of
waning immunity after 10 years of vaccination, the cost of vaccination exceeded $140,000 per
QALY, highlighting the importance of including the vaccine’s efficacy in this paper’s analysis.
In this dynamic modeling approach, the discount rate used was 3% annually, and the benefit of
this model is that it estimates the direct health benefits to people that were vaccinated as well as
the unvaccinated benefitting from herd immunity.113 This study delves further into the impacts of
screening changes; however, the present research paper will only be including the effects of a
vaccination program, holding the current cervical cancer screening practices constant. Another
limitation of the present analysis, which is highlighted below, is that it does not include
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discussions of what would constitute this vaccine being cost-effective for men, especially if
cancer screening for male HPV-related cancers is less prevalent in a common medical physical.
10.4. Cost-Effectiveness for Men
Even though the vaccine has had a longer history of use in females, oropharyngeal cancer
caused by HPV has high prevalence in males. In their study, Marc Ryser et al. use an agentbased modeling framework to assess the impact of coverage-dependent marginal vaccination
costs to determine the value of vaccinating adolescent males in addition to females.114 They use a
sample of sexually active adolescents, divided equally between males and females, and run
simulations to determine the infection and transmissibility of HPV without vaccination. Then
simulations are run that factor in vaccination at its 2009 rate to identify the costs and benefits of
the program.115 Ryser et al. examine this by running a model where vaccine uptake levels are
negatively correlated with sexual activity, and another where uptake is positively correlated, as
there is the assumption that vaccination impacts future sexual activity. The limitation of this
method is that sexual activity for adolescents is not numerically quantified in this paper, meaning
that relationship and sexual relations patterns could change the results. The paper does overall
find that the male marginal costs of vaccination are 25-50% higher than the female marginal cost
therefore indicating that the most cost-effective vaccination policy so far is vaccinating only
women.116 This is a jumping off point for what I can expect to find in the current paper’s study.
In fact, Harrell Chesson et al. reiterate this finding in their paper, finding that costeffectiveness of male vaccination depends on female vaccination rates and that increasing female
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vaccination coverage is probably more efficient.117 The limitation is that this comparison draws a
cost-effectiveness distinction between female and male vaccination campaigns but does not
answer or provide evidence that either are cost-effective by themselves.
In a study done in Italy to determine the cost-effectiveness of HPV vaccination in
adolescent males, Ersilia Sinisgalli et al., conducted a systematic meta-analysis. Eleven articles
were identified by the criteria set and their data collected to find that only 53% of the results
deemed vaccinating males to be cost-effective.118 The rest found it only to be effective for
women to prevent cervical cancer. This paper indicates that male vaccination is potentially not as
cost-effective, which will be tested in this current paper, but that the subject is also not as studied
as the cost-effectiveness for adolescent females.
In their meta-analysis, Mohamed-Béchir Ben Hadj Yahia et al., found a result similar to
Sinisgalli et al.’s, but indicated that targeting vaccination of homosexual men could be costeffective.119 17 studies and 12 different models were analyzed and found that if cervical cancer is
the only targeted disease for the vaccine, vaccinating men and women reaps a $64,764/QALY
benefit compared to vaccinating only women.120 When the potential benefit of all HPV-related
diseases was factored into the model and there was a 75% vaccination rate, the estimated ICER
went up to $202,785/QALY, exceeding the cost-effective threshold set by the World Health
Organization of $50,000/QALY.121 The results point to cost-effectiveness of vaccinating males
being present only if female vaccination rates are lagging behind 40%, something that will be
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explored in further literature. This offers a foundation for which to interpret this paper’s results
when the male cost-effectiveness model for preventing OPC cases and deaths is conducted.
10.5. Cost-effectiveness Outside the United States
In a meta-analysis by Rashidul Mahumud et al., cost-effectiveness across 12 studies was
compared by examining whether the ICER/DALYs (disability adjusted life years) averted was
less than three times the country’s per capita Gross Domestic Product (GDP).122 Nine studies
examined this question using a dynamic model similar this current paper’s model, two used a
static model, and one used the Markov model. In all, ten of the featured studies concluded that
the 9vHPV vaccine was cost-effective, four of which found this true in gender-neutral
vaccination policies.123 Overall, this article details an overwhelming consensus in the economic
community is that the HPV vaccine is cost-effective for adolescent females, but it does not detail
whether this is true for males. This study will recreate the study analyzing the effects on females
as well as performing a study on men both with full vaccination and current vaccination rates.
As described by parental concerns in section seven of this paper, necessity of the vaccine
with the prevalence of pap smears was debated. In a study analyzing whether a national HPV
screening program alone or paired with an HPV vaccination program was cost-effective in
Nigeria, Obinna Ekwunife and Stefan Lhachimi created a microsimulation framework following
one million women.124 To identify the suitable cervical cancer prevention policy, an incremental
costs-effectiveness ratio (ICER) was used to represent the average incremental cost associated
with one additional disability adjusted life year (DALY) averted when discounted at a rate of
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3%.125 The result indicated that the paired program resulted in an aversion of $7,930/DALY
which proved cost-effectiveness against the threshold of $9,610/DALY set by the authors.126
However, the screening program alone did not prove to be cost-effective in Nigeria. This study
offers insight into how cost-effectiveness of HPV vaccination can be measured in a developing
country and what results could be found by running a similar analysis in the United States.
A similar study was conducted by Ariel Bardach et al. to study the cost-effectiveness of
implementing a bivalent or quadrivalent vaccination scheme in comparison to the current policy
of vaccination in Venezuela. This study used a Markov cohort model that simulated the natural
history of HPV in cervical cancer incidence while including just screening practices vs. with
quadrivalent or bivalent vaccinations.127 Expected costs of cancer screening and treatments were
estimated using a micro-costing approach using data from the Oncologic Institute in Caracas,
Venezuela. The health outcomes in this paper were measured in QALYs and number of cancer
cases and deaths. An important contribution of this paper is that the probability of a vaccine
being cost-effective depends heavily on the pricing, which will be considered in this research
paper’s discussion. Another limitation of this paper, like other papers described above is that
male cost-effectiveness was not considered.
11. MODEL
As explained by health economist David Meltzer, expected utility provides a framework
for analyzing the effects of changing medical expenditures on one’s lifetime utility. Medical
interventions, such as immunization, affect one’s expected utility by changing survival
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probabilities and health quality during life and this produces two costs of the intervention.128
These two costs are the direct intervention cost and the net expenditures due to the change in
survival probabilities. Cost-benefit analysis done in this paper uses the utility maximization
principle that allocation of resources should produce benefits of the same amount of extra utility
gained per individual. The idea of diminishing marginal returns to utility will also be used in this
paper because there is a level of herd immunity (85% vaccination) that can be reached where
vaccinating additional individuals produces a significantly lower societal benefit. The goal of
this study is to analyze whether investing in full United States adolescent vaccination offers
benefits producing at least the same utility as the next best option.
This study also encapsulates a social dilemma where the decision to vaccinate entails a
choice between taking on a substantial cost now or getting an illness with a larger cost of
treatment later. In a classic social dilemma scenario, individuals are better off defecting
regardless of what the other does. However, if all individuals defect, everyone is made worse off
than if all cooperated, which would mean no inoculation due to its high price tag. Therefore,
discounting delayed outcomes will enable cost-effectiveness to be analyzed to see whether the
individual and societal benefit of vaccinating everyone is economically effective, especially if
the benefits would not be reaped for several decades.
Economically, the principle of discounting can apply to healthcare program analysis,
especially those at which most of the costs are incurred presently and benefits occur farther in the
future.129 The idea of discounting is based on the economic concept of “positive time preference”
meaning that due to an assumption that humans are rational, society prefers to benefit from
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consumption sooner rather than later.130 In this model, uniform discounting will be used as the
impact of time is independent of the nature of future events and to preserve consistency in costs
and benefits that yield outcomes at different points in time. Current practice in economic
evaluation is to use a uniform discount rate of 3% for the first 30 years of analysis and that the
rate may decrease over a greater length of time due to diminishing marginal utility of benefits.
As discussed in section nine, most previous literature has utilized a discount rate of 2-4% when
measuring benefits and costs of implementing a healthcare program, and an average of 3% is the
rate that this present study will use.
In this study’s model, we analyze the benefit of treating a group of 100,000 people by
medical and mortality costs saved versus the cost of the full-dose vaccine administration. My
base case for this analysis will be the cost-effectiveness if no female or male is vaccinated. In
addition, I will discount back the benefits received in cervical cancer prevention a certain
number of years after the vaccine (defined in the next section) to today’s dollars. The benefit is
measured as the total cost of treating all patients with cervical cancer minus the cost of life lost in
the patients that die of the ailment discounted back a certain number of years. The cost of life
lost is measured between the average age of cervical cancer diagnosis for United States women
to the average life expectancy of United States women. This model will serve as a baseline to
estimate cost-effectiveness of the vaccine for women, after which the current rate of vaccination
and full vaccination rate will also be tested for the vaccine’s cost-effectiveness. I will then test all
three cases for the remaining ages to see if age of inoculation affects the vaccine’s effectiveness.
Once the trial is completed for women, I conduct the same model for men but by using
the incidences and death of oropharyngeal cancer (OPC) in men as it is the most prevalent HPV
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related cancer for men. The assumptions made for the variables used in building and conducting
this model are:
I. The number of cervical cancer and OPC cases and deaths for women and men, respectively,
are taken from the CDC’s Cancer Statistics Data. The total number of women diagnosed with
cervical cancer out of 100,000 women in 2007 was 8.0, 3.0 of whom died.131 The total
number of men diagnosed with OPC out of 100,000 men in 2007 was 17.0, 4.0 of whom
died.132 To represent the base-case scenario, the 2007 cancer numbers (before vaccination)
will be used. These values will be used in the model to calculate the cost of treatment for all
cancer cases and the cost of life lost for the mortal cases.
II. The average age of diagnosis of the individual cancers tested will be taken from the
American Society of Clinical Oncology and used to calculate how long the effects of
vaccination for each age tested would take to cause an effect. This age of effect will be
represented by the average age of cancer incidence (diagnosis), denoted as 49 years of age
for cervical cancer in women and 62 years of age for OPC in men.133134
III. The discount rate represents the social opportunity cost of investing in the vaccination
program instead of the “next-best” alternative program. A consensus among previous
literature detailed in section 10 is to use a 3% discount rate on costs and benefits when
measuring cost-effectiveness of healthcare programs.
IV. The cost of death/life lost will be used to measure the benefits of cancer death prevention in
this model. The cost of life lost will be the average income one would have earned each year
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modified 2018.
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from the age of death to the age of retirement (designated as 67).135 Using data from the
United States Census Bureau, the average income of a male between the ages of 45 and 64 in
2018 was $77,878 and the average income of a female between the ages of 45-64 in 2018
was $47,913.136 These income values are what will be used as a measurement of life lost per
year for the current vaccination and full vaccination calculations. The 2007 average income
values for women between the ages of 45 and 54 years old was $37,645 and for men between
the ages of 55 and 64 years old was $58,800.137
a. Although most previous literature have used QALYs to measure value of life lost, this
model will assume equal quality of life lost and will value an individual’s life without
including potential spillover effects. QALYs have also been subject to scrutiny by
economists due to the subjective way of quantifying one’s value to society.
b. Previous literature shows estimates of annual direct medical costs of preventing and
treating HPV-associated diseases, including cervical cancer and OPC. The baseline
cost per case of cervical cancer in 2010 U.S. dollars was $38,800 and the baseline
cost per case of OPC in 2010 U.S. dollars was $43,200.138 This model will convert
these values into 2018 U.S. dollars for the current-vaccination and full-vaccination
modeling, and 2007 U.S. dollars for the no-vaccination model by using the Bureau of
Labor Statistics’ Consumer Price Index (CPI) for Medical Care.139 The values can be
converted due to the assumption that medical technologies and cost of care have not
135
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changed dramatically in eight years. Therefore, this model assumes that the average
cost of cancer treatment has gone up at the same rate as average general medical
costs. The CPI calculations are as follows:
Reference Base: 2008-2010
January 2010 CPI: 400.24
January 2007 CPI: 351.07
Index Point Change: 351.07 − 400.24 = −49.17
−49.17
Percent Change: 400.24 = −0.123 ∗ 100 = −12.3%
Cervical Cancer Treatment Cost in 2007: 38,800 ∗ 0.877 = $34,027.60
OPC Treatment Cost in 2007: 43,200 ∗ 0.877 = $37,886.40
Reference Base: 2010-2018
January 2010 CPI: 400.24
January 2018 CPI: 484.70
Index Point Change: 484.70 − 400.24 = 84.46
84.46
Percent Change: 400.24 = 0.211 ∗ 100 = 21.1%
Cervical Cancer Treatment Cost in 2018: 38,800 ∗ 1.211 = $46,986.80
OPC Treatment Cost in 2018: 43,200 ∗ 1.211 = $52,315.20
c. According to the vaccine database, in 2018 the 9vHPV vaccine’s CDC cost was
$168.10 and the vaccine’s private sector cost was $217.11.140 For this model, an
average price of $192.61 per dose will be used. Since each vaccination in this model
is defined as a two-dose set, the total average price of vaccinating an individual is
$385.22. A limitation is that the price of the vaccine used in this study will not
include considerations of vaccine delivery costs, which could raise the price of
administration.
d. The second scenario that will be modelled in this study is whether the vaccine is costeffective in trying to advance vaccination rates past current levels. The current
vaccination levels for up to date (UTD) vaccination in 2018 for adolescent females,

140
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based on the CDC NIS data, was 54% and 49% for males.141 These are the
vaccination rates that will be used to represent the current vaccination rates in the
model.
12. DATA
A large piece of the data used in this model are the vaccination rates for adolescents per
year broken down into different demographic groups. This data is compiled from the annual
National Immunization Survey for Teens published by the Center for Disease Control and
Prevention (CDC).142 This survey is a random-digit-dialed survey of parents or guardians of
20,000 randomly selected adolescents, between the ages of 13 and 17, each year. Every year, the
vaccination data of these individuals are compiled into a panel-formatted data set that reports the
percentage of the randomly sampled survey respondents who are up to date on a particular
vaccine or who, in the case of HPV vaccination, received one dose out of the two recommended.
The data also breaks the percentages down by each age between 13 and 17 years old, gender, and
for whether they live in a Metropolitan Statistical Area (MSA). Although data has been collected
for HPV vaccines since 2011, I will be using the 2018 vaccination data for the vaccination rates
of men and women in my model as it is the most comprehensive and recent data.

NIS-Teen Survey, “TeenVaxView Publications and Resources,” Center for Disease Control and Prevention, last
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Table 1. 2018 Vaccination Rates for Males and Females Based on Dose Amount and Age
Dosage (Sex)
1 Dose (Female)
95% CI Upper Bound
95% CI Lower Bound
UTD (Female)
95% CI Upper Bound
95% CI Lower Bound
1 Dose (Male)
95% CI Upper Bound
95% CI Lower Bound
UTD (Male)
95% CI Upper Bound
95% CI Lower Bound
1 Dose (All)
95% CI Upper Bound
95% CI Lower Bound
UTD (All)
95% CI Upper Bound
95% CI Lower Bound
Count

13
61.1
65.2
56.9
38.9
42.9
35
64.0
67.9
59.9
40.9
45.3
36.5
62.6
65.4
59.7
39.9
42.9
37.0
3,455

2018 Age (years)
14
15
16
68.6
70.7
73.5
72.5
74.5
76.8
64.4
66.5
69.8
52.7
54.7
57.5
56.8
59.0
61.6
48.5
50.4
53.3
65.1
68.7
69.2
68.7
72.1
73.0
61.3
65.0
65.2
47.7
53.2
51.8
51.8
57.3
56.1
43.6
49.1
47.5
66.9
69.7
71.2
69.6
72.3
73.8
64.1
66.9
68.5
50.3
54
54.5
53.2
56.9
57.5
47.3
51.0
51.5
3,641
3,666
3,731

17
76.3
80.0
72.2
66.0
70.1
61.8
64.7
68.5
60.7
50.0
54.3
45.7
70.1
72.8
67.3
57.5
60.5
54.4
3,342

Composite (%)
2018
69.9
71.6
68.1
53.7
55.6
51.8
66.3
68.0
64.6
48.7
50.6
46.8
68.1
69.3
66.8
51.1
52.5
49.8
17,835

Source: NIS-Teen Survey, “TeenVaxView Publications and Resources,” Center for Disease Control and Prevention, last modified 2021.
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13. RESULTS
The first part of the comparison that will be done is calculating how much it costs to
vaccinate 100,000 people at the 2018 vaccination rate compared to the costs of treatment
foregone and life lost. The values in Table 2 are represented by the following variables:
-

Column II represents the age at which the female or male adolescent was fully vaccinated
against HPV in 2018.

-

Column III represents the costs of cervical cancer and OPC treatment and death foregone
by vaccinating at 2018 rates. The cost values for each age and gender are calculated using
the below equation:
Equation 1
𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
[
(1 + 𝑑𝑖𝑠𝑐𝑜𝑢𝑛𝑡 𝑟𝑎𝑡𝑒)(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑔𝑒 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠−𝑎𝑔𝑒 𝑜𝑓 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛)
∗ (# 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑎𝑛𝑐𝑒𝑟 𝑝𝑒𝑟 100,000 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠)] +

{

𝑜𝑓 𝑟𝑒𝑡𝑖𝑟𝑒𝑚𝑒𝑛𝑡−1
∑𝑎𝑔𝑒
𝑛=𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑔𝑒 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑎𝑖𝑛 (

67−𝑛
1
)
(1 + 𝑟)

(1 + 𝑑𝑖𝑠𝑐𝑜𝑢𝑛𝑡 𝑟𝑎𝑡𝑒)(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑔𝑒 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠−𝑎𝑔𝑒 𝑜𝑓 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛)
∗ (#𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑑𝑦𝑖𝑛𝑔 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑝𝑒𝑟 100,000 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠)}

-

The above equation represents the calculations for the baseline values. The same equation
will then be used with the current vaccination rate and the difference in costs between the
two numbers per age and gender are the values displayed in Column III.

-

Column IV represents the number of people that would be fully vaccinated in 2018 for
every 100,000 people.

-

Column V represents the cost of vaccinating the number of people in column IV,
calculated by:
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 𝑓𝑢𝑙𝑙𝑦 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 𝑖𝑛 2018 ∗ (𝑡𝑤𝑜 𝑑𝑜𝑠𝑒 𝑣𝑎𝑐𝑐𝑖𝑛𝑒 𝑝𝑟𝑖𝑐𝑒)
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-

Column VI represents the cost ratio between columns III and V, calculated by:
𝐶𝑜𝑙𝑢𝑚𝑛 𝑉
𝐶𝑜𝑙𝑢𝑚𝑛 𝐼𝐼𝐼

Table 2. Cost and Benefit Evaluation between Baseline Math and 2018 Vaccination Rates
I

II

Gender

Age of
Vaccination

Female

13
14
15
16
17

III
Treatment and
Death Costs
Foregone with
Vaccination
$ 102,261.46
$ 209,179.12
$ 230,956.71
$ 260,239.61
$ 337,943.58

Male

13
14
15
16
17

$ 60,556.20
$ 96,673.49
$ 128,149.12
$ 124,501.64
$ 118,315.20

IV
People
Getting
Vaccines
per 100,000
38,900
52,700
54,700
57,500
66,000

V

$ 14,985,058.00
$ 20,301,094.00
$ 21,071,534.00
$ 22,150,150.00
$ 25,424,520.00

VI
Cost Ratio
Between
Columns III
and V
14,654
9,705
9,124
8,511
7,523

40,900
47,700
53,200
51,800
50,000

$ 15,755,498.00
$ 18,374,994.00
$ 20,493,704.00
$ 19,954,396.00
$ 19,261,000.00

26,018
19,007
15,992
16,027
16,279

Vaccine Cost

Source: The data used to calculate these values were compiled from various sources and explained in the Model section of this paper.

Table 2 demonstrates how much money is expected to have been saved in cervical
cancer/OPC treatment and death costs due to the vaccination rates in 2018. The comparison is
between the future savings from vaccinating at 2018 rates and if there had been no vaccination.
By comparing columns III and V, one can determine that the cost of vaccination at the 2018 rates
are between 7,523-14,654 times higher than the costs foregone (depending on the age and gender
of the vaccinated individual). Therefore, the vaccination in 2018 was not cost-effective when
comparing the treatment and death costs foregone and the 2018 price of the two-dose vaccine.
The second comparison that will be done is comparing the additional costs and benefits
of maximizing the vaccination rate by raising the vaccination rate from its 2018 level to 100% of
the population. The values in Table 3 are represented by the following variables:

64

Jammes 65
I.

Column II represents the age at which the female or male adolescent was fully
vaccinated against HPV in 2018.
a. Column III represents the difference between the costs foregone calculated
with 100% vaccination rates and those in Table 2 Column III. The values for
each age and gender are calculated using the following steps:
1. Performing the calculations demonstrated in Equation 1 using
the fully vaccinated values.
2. Taking the difference between the costs calculated in the
baseline trial and those calculated in step 1.
3. Then taking the difference between the values in Table 2
Column III and those calculated in step 2.
b. Column IV represents the additional number of people that would be fully
vaccinated in 2018 for every 100,000 people if the vaccination rates were
increased to 100%. Calculated by:
(100 − 2018 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒) ∗ 100,000
c. Column V represents the cost of vaccinating the number of people in column
IV. Calculated by:
𝑐𝑜𝑙𝑢𝑚𝑛 𝐼𝑉 𝑣𝑎𝑙𝑢𝑒𝑠 ∗ (𝑡𝑤𝑜 𝑑𝑜𝑠𝑒 𝑣𝑎𝑐𝑐𝑖𝑛𝑒 𝑝𝑟𝑖𝑐𝑒)

d. Column VI represents the cost ratio between columns III and V, calculated by:
𝐶𝑜𝑙𝑢𝑚𝑛 𝑉
𝐶𝑜𝑙𝑢𝑚𝑛 𝐼𝐼𝐼
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Table 3. Cost and Benefit Evaluation between 2018 Vaccination Rates and Full Vaccination
I

II

III

21,081.87
125,564.13
144,833.27
171,532.47
246,575.23

IV
Additional #
of People
Getting
Vaccines per
100,000
61,100
47,300
45,300
42,500
34,000

Gender

Age of
Vaccination

Costs Foregone
by fully
vaccinating from
current rates

Female

13
14
15
16
17

$
$
$
$
$

Male

13
14
15
16
17

$
$
$
$
$

V

$ 23,536,942.00
$ 18,220,906.00
$ 17,450,466.00
$ 16,371,850.00
$ 13,097,480.00

111,645
14,511
12,049
9,544
5,312

6,141.90
40,626.76
70,420.99
65,041.66
57,071.42

59,100
52,300
46,800
48,200
50,000

$ 22,766,502.00
$ 20,147,006.00
$ 18,028,296.00
$ 18,567,604.00
$ 19,261,000.00

370,675
49,590
25,601
28,547
33,749

Additional
Vaccine Cost

VI
Cost Ratio
Between
Columns III and
V

Source: The data used to calculate these values were compiled from various sources and explained in the Model section of this paper.

Table 3 demonstrates how much money could be expected to be additionally saved in
terms of future cervical cancer/OPC treatment and death costs if vaccination rates had been
100% in 2018, compared to the actual 2018 rates. The comparison is between the additional
future savings from vaccinating at 100% rates compared to those at the 2018 rate of vaccination.
The additional vaccine cost is the additional costs associated with vaccinating the people that
were not vaccinated under the 2018 rates. By comparing columns III and V, we show the cost of
moving society from 2018 vaccination rates to full vaccination is between 5,312-111,645 times
higher than the costs foregone (depending on the age and gender of the vaccinated individual).
Therefore, vaccinating at 100% instead of 2018 vaccination rates would not have been costeffective when comparing the additional treatment and death costs foregone and the 2018 price
of the two-dose vaccine.
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14. LIMITATIONS
There are two main limitations of these results that offer potential for future research. The
first is that my study only uses the costs foregone associated with costs of cancer treatment and
death; it does not include the vaccine’s ability to lower the incidence of pre-cancerous lesions.
This demonstrates that the vaccine has a wider positive effect on the medical community than is
defined in this paper and it is possible that the vaccine’s benefits could reduce the use of certain
medical treatments, including pre-cancer treatments.
The second limitation of this study is that the marginal benefit calculation does not
include a partial externality of vaccination to society in the form of herd immunity. This was
excluded from this model’s calculations due to the difficulty of quantifying these effects but
could produce a positive impact on the costs foregone due to vaccination. Depending on how
much of an impact the herd immunity effects have on the costs foregone, the cost-effectiveness
of the vaccine could change.
15. COST-EFFECTIVENESS DISCUSSION
This study aimed to examine whether the benefits accrued by rolling out the HPV
Gardasil-9 vaccine in the long term justified the high price tag needed to be paid for today. The
benefits accrued were measured by the cost of treating cervical cancer/OPC (depending on the
individual’s sex) and the cost of loss of life from the people that died of the illness. The costs of
the vaccine were determined by the average market price of the vaccine published by the CDC.
The total cost of treatment and death were calculated for every population of 100,000 individuals
using cancer rates from the CDC and discounted at a rate of 3% to determine how much the costs
would be without vaccination in today’s dollars. Then the same calculations were conducted for
the 2018 rate of vaccination and full vaccination to identify how the additional benefits of costs
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foregone would compare to the costs of vaccinating the individuals. The comparison yielded that
neither the campaign to vaccinate at 2018 levels, nor the goal of fully vaccinating adolescents
was cost-effective at the current price of the Gardasil-9 vaccine. This demonstrates that
vaccinating adolescent females and males with the current price may not have been the best use
of funding in order to prevent cervical cancer and OPC.
A potential avenue for future cost-effectiveness research on the HPV vaccine is to study
the cost-effectiveness of the vaccine at a price outside of it current patented one and with a
different dosage schedule. It is possible that if either of these vaccine factors changed the costeffectiveness could as well. For example, if the patent expired, it is possible that the vaccine
could become cost-effective. However, based on the results in section 13, the vaccine’s price
would have to fall to 1.5% or less of its current price to make it cost-effective for females and to
0.3% of its current price for males, vaccinated at age 17, and even lower for the other ages of
vaccination.
There are studies that demonstrate promise for the vaccine to be as effective at a one-dose
efficacy as it is at the current two-dose efficacy. In their study, Joshi et al. conducted a multicenter cluster randomized trial of one vs. two vs. three doses of the quadrivalent HPV vaccine.
The studied analyzes the antibody production of 18,000 unmarried girls aged 10-18 years over a
48 month period divided into four vaccination groups: a three-dose group, two two-dose groups,
and a one-dose group.143 The study found that the frequencies of cumulative incident HPV 16
and 18 infections over 7 years from vaccination were similar across all vaccinated groups and
that the antibody titers for HPV 16 and 18 increased over the study period in one-dose
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recipients.144 The HPV prevalence among unvaccinated women in the study was higher than the
group receiving one-dose, indicating the single-dose schedule’s potential to provide robust
protection. Further research, especially regarding the single-dose efficacy of the new Gardasil-9
vaccine is required before a single-dose efficacy can be put in place to replace the current twodose schedule. If this change occurs, then the price of vaccinating an individual would be cut in
half, potentially affecting the vaccine’s cost-effectiveness.
These results should be prefaced with the statement that this paper is not intended to
discount the suffering of the people who suffer from cervical cancer or OPC, but to address
where the best use of resources is to help the largest number of people. Contrary to much of the
existing literature, this paper demonstrates that HPV vaccination is not cost-effective in the
United States given the current price of the Gardasil-9 vaccine.
16. CONCLUSION
This analysis finds that there were two underlying assumptions within the CDC/FDA
prescriptions during the three main events in the HPV vaccine timeline. The two assumptions
were that the language initially placed a larger burden on women to protect society’s
reproductive health and that there was a greater concern for female over male long-term health.
These two assumptions shaped parental concerns and media response to the vaccine, to a point
that has hindered uptake rates and shaped the feminization of the vaccine. A central question that
the parental discussion unveiled was the heavily marketed nature of the vaccine and the question
of how profitability had been affecting the HPV vaccine discussion. To understand the efficacy
and necessity of the vaccine, this paper also found that the 9vGardasil vaccine was not costeffective at 2018 inoculation levels nor at 100% vaccination. Therefore, with the current price of
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the vaccine and oropharyngeal and cervical cancer treatments, investing in increasing the uptake
rates of vaccination is not the most efficient use of financial resources.
A potential avenue for expanding this research is to do a similar analysis of parental
concerns and economic benefits for certain populations in the United States to determine if a
targeted inoculation campaign could be efficient and beneficial for long-term societal health.
This could include analyzing the impact of income level, insurance status, or a non-patented
vaccine price.
By combining the fields of STS and Economics, this paper offers a comprehensive view
on the ideas behind parental concerns regarding vaccination. The STS portion was focused on an
individual level impact of the prescriptions, whereas the Economics portion took a more societal
lens. Both are helpful is building a comprehensive understanding of HPV vaccine politics. Costeffectiveness analysis is key in health economics to determine whether financial resources should
be invested into a program and STS analysis is used to dig deeper into why the scientific
discussion evolved in a certain way. As a large parental concern over HPV vaccination was the
belief that it was a large marketing push, identifying whether the vaccine is cost-effective in
preventing certain cancers offers greater insight into the importance of the parental discussions.
This offers some credibility to the parental concerns and the idea that a different approach to
reducing cervical cancer cases would be beneficial to explore.
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